Applied Genetic Technologies Corporation (NASDAQ:AGTC) – Equities researchers at Cantor Fitzgerald issued their FY2019 EPS estimates for Applied Genetic Technologies in a research note issued to investors on Monday. Cantor Fitzgerald analyst M. Goldstein forecasts that the biotechnology company will post earnings per share of ($2.51) for the year. Cantor Fitzgerald currently has a “Hold” rating and a $9.00 target price on the stock.
A number of other research firms have also recently commented on AGTC. Wedbush restated an “outperform” rating and issued a $9.00 price objective on shares of Applied Genetic Technologies in a research report on Wednesday, November 8th. ValuEngine cut shares of Applied Genetic Technologies from a “sell” rating to a “strong sell” rating in a research report on Sunday. Zacks Investment Research cut shares of Applied Genetic Technologies from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 31st. HC Wainwright restated a “buy” rating and issued a $8.00 price objective (down previously from $16.00) on shares of Applied Genetic Technologies in a research report on Thursday, September 14th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $7.00 price objective (down previously from $14.00) on shares of Applied Genetic Technologies in a research report on Thursday, September 14th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $10.17.
A number of hedge funds have recently added to or reduced their stakes in AGTC. Nine Chapters Capital Management LLC bought a new position in Applied Genetic Technologies during the 3rd quarter worth about $113,000. Citadel Advisors LLC increased its holdings in Applied Genetic Technologies by 304.6% during the 3rd quarter. Citadel Advisors LLC now owns 41,270 shares of the biotechnology company’s stock worth $163,000 after purchasing an additional 31,070 shares in the last quarter. Virtu KCG Holdings LLC bought a new position in Applied Genetic Technologies during the 2nd quarter worth about $178,000. Credit Suisse AG increased its holdings in Applied Genetic Technologies by 10.9% during the 1st quarter. Credit Suisse AG now owns 27,110 shares of the biotechnology company’s stock worth $187,000 after purchasing an additional 2,662 shares in the last quarter. Finally, ClariVest Asset Management LLC increased its holdings in Applied Genetic Technologies by 18.5% during the 3rd quarter. ClariVest Asset Management LLC now owns 99,013 shares of the biotechnology company’s stock worth $391,000 after purchasing an additional 15,491 shares in the last quarter. Hedge funds and other institutional investors own 46.83% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Analysts Issue Forecasts for Applied Genetic Technologies Corporation’s FY2019 Earnings (AGTC)” was posted by American Banking News and is the property of of American Banking News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/01/04/analysts-issue-forecasts-for-applied-genetic-technologies-corporations-fy2019-earnings-agtc.html.
About Applied Genetic Technologies
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).
Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.